Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep 20;25(18):4207-14.
doi: 10.1038/sj.emboj.7601314. Epub 2006 Aug 31.

EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN

Mrinal Samanta  1 , Dai Iwakiri, Teru Kanda, Tadaatsu Imaizumi, Kenzo Takada
Affiliations

EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN

Mrinal Samanta et al. EMBO J. .

Abstract

Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) are nonpolyadenylated, untranslated RNAs, exist most abundantly in latently EBV-infected cells, and are expected to show secondary structures with many short stem-loops. Retinoic acid-inducible gene I (RIG-I) is a cytosolic protein that detects viral double-stranded RNA (dsRNA) inside the cell and initiates signaling pathways leading to the induction of protective cellular genes, including type I interferons (IFNs). We investigated whether EBERs were recognized by RIG-I as dsRNA. Transfection of RIG-I plasmid induced IFNs and IFN-stimulated genes (ISGs) in EBV-positive Burkitt's lymphoma (BL) cells, but not in their EBV-negative counterparts or EBER-knockout EBV-infected BL cells. Transfection of EBER plasmid or in vitro-synthesized EBERs induced expression of type I IFNs and ISGs in RIG-I-expressing, EBV-negative BL cells, but not in RIG-I-minus counterparts. EBERs activated RIG-I's substrates, NF-kappaB and IFN regulatory factor 3, which were necessary for type I IFN activation. It was also shown that EBERs co-precipitated with RIG-I. These results indicate that EBERs are recognized by RIG-I and activate signaling to induce type I IFN in EBV-infected cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
RIG-I induces type I IFN in EBV-infected cells. EBV-positive Mutu cells (Mutu(+)) and EBV-negative Mutu cells (Mutu(−)) (5 × 106 each) were transfected with 30 μg of GFP-tagged RIG-I plasmid or control GFP plasmid, and expression of IFNs and ISG56 was examined at the designated time by RT–PCR. (A) Immunoblot analysis for detection of RIG-I. The blots were probed with anti-RIG-I antibody (left panel) and anti-GFP antibody (right panel). Cell lysates were prepared after 24 h of transfection and 20 μg of protein sample was loaded per slot. (B) RT–PCR analysis of expression of IFN-α, IFN-β, and ISG56 in Mutu (+) cells. (C) RT–PCR analysis of expression of IFN-α, IFN-β, and ISG56 in Mutu (−) cells. (D) RT–PCR analysis of EBER1 expression in Mutu(+) and Mutu(−) cells.
Figure 2
Figure 2
RIG-I induces type I IFN in EBER-expressing cells. BL-derived, EBER-positive and EBER-negative Akata cells (5 × 106 each) were transfected with 30 μg of GFP-tagged RIG-I plasmid or GFP plasmid, and expression of IFN-β and ISG56 was examined at the designated time by RT–PCR. (A) Expression of IFN-β and ISG56 in Akata cells infected with EBER-knockout EBV (EBER(−) EBV) or EBER-reintroduced EBV (EBER(+) EBV). After 12 h of transfection of the RIG-I plasmid or control plasmid, cells were subjected to RT–PCR analysis. (B) Expression of IFN-β and ISG56 in Akata cells stably transfected with EBER plasmid (Akt/EBER) or in those with control plasmid carrying the neomycin resistance gene (Akt/Neor). After 6 and 12 h of transfection of the RIG-I plasmid or GFP plasmid, cells were subjected to RT–PCR analysis. (C) EBER-positive EBV-infected and EBER-negative EBV-infected Akata cells were transfected with 100 nM of RIG-I siRNA or control siRNA. After 24 h, expression of RIG-I and IFN-β was checked by RT–PCR. (D) EBER-expressing Akata cells and control cells were also transfected with 100 nM of RIG-I siRNA/control siRNA and the expression of RIG-I and IFN-β was examined at 24 h post-transfection.
Figure 3
Figure 3
EBERs induce type I IFN in RIG-I-expressing cell clones. EBV-negative Daudi cells were transfected with the plasmid carrying GFP-tagged RIG-I or control plasmid carrying the GFP gene only, and cell clones stably expressing RIG-I/GFP or GFP were isolated. They (5 × 106 each) were transfected with 30 μg of EBER plasmid, and expression of type I IFN was examined at the designated time by RT–PCR. (A) Immunoblot analysis for detection of RIG-I. The blots were probed with the anti-GFP antibody. Protein samples amounting to 20 μg was loaded per slot. (B) RT–PCR analysis for detection of IFN-β.
Figure 4
Figure 4
Both EBER1 and EBER2 activate RIG-I to induce type I IFN. (A) Analysis of in vitro-synthesized EBER1 and EBER2 in 5% denaturing PAGE before (left panel) and after (middle panel) RNase A treatment. RT–PCR analysis of EBER1 cDNA with EBER1 and EBER2 primers and also EBER2 cDNA with EBER2 and EBER1 primers (right panel). (B) RT–PCR analysis of expression of IFN-β, ISG56, and ISG15 after transfection of EBER1 and EBER2. RIG-I- or GFP- (5 × 106 each) expressing stable clones were transfected with 30 μg of EBER1 or EBER2, separately or in combination (1:1). Expression of IFN-β and ISGs was examined after 6 and 24 h of transfection.
Figure 5
Figure 5
EBERs activate NF-κB and IRF-3. (A) Phosphorylation of NF-κB in RIG-I- or GFP-expressing stable clone was analyzed after they (5 × 106 cells each) were transfected with 30 μg of in vitro-synthesized EBERs (1:1) or polyI:C (positive control). After 6 h of transfection, whole-cell lysates (20 μg of protein for each sample) were subjected to immunoblot analysis for detection of phosphorylated NF-κB. (B) NF-κB reporter assay. NF-κB plasmid was transfected into both RIG-I-expressing Daudi cell clone and control clone and after 36 h of transfection, EBERs or polyI:C were transfected. After 12 h of EBER or polyI:C transfection, luciferase activity was measured in cell lysates (Figure 5B). Results are shown as the means±standard errors from three independent experiments. (C) Effect of IκB-α, a specific inhibitor of NF-κB, on EBER-induced phosphorylation of NF-κB. RIG-I-expressing stable clones (5 × 106 cells) were first transfected with 10 μg (+) or 20 μg (++) of IκB-α plasmid. After 36 h, they were further transfected with 30 μg of in vitro-synthesized EBERs (1:1), and expression of IFN-β was examined by RT–PCR after 8 h of transfection. (D) Inhibition of NF-κB activation by IκB-α plasmid. RIG-I-expressing stable clones (5 × 106 cells) were transfected with 10 μg of pNF-κB/luc (firefly luciferase) and 100 ng of pCMV/luc (Renilla luciferase as an internal control), along with 10 μg (+) or 20 μg (++) of IκB-α plasmid. After 36 h, luciferase activity was quantified in cell lysates using a Dual-Luciferase reporter assay system (Promega). Results are shown as the means±standard errors from three independent experiments. (E) Phosphorylation of IRF-3 in EBV-negative Daudi cells stably expressing RIG-I. RIG-I- or GFP- (5 × 106 cells each) expressing stable clones were transfected with 30 μg of in vitro-synthesized EBERs (15 μg each) or polyI:C (positive control). After 2 and 6 h of transfection, whole-cell lysates (30 μg of protein for each sample) were separated with native PAGE gel (8%) to analyze the phosphorylation of IRF-3 by EBERs or polyI:C. The blot was probed with anti-phosho-IRF-3 antibody. This antibody reacted with phosphorylated IRF-3, but not with unphosphorylated IRF-3. (F) RIG-I-expressing stable clone was treated with 100 nM of IRF-3 siRNA or control siRNA. After 24 h, cells were transfected with 30 μg of in vitro-synthesized EBERs, and 6 h later, expression of IRF-3, IFN-β, and ISG56 was examined by RT–PCR.
Figure 6
Figure 6
EBER is recognized by full-length RIG-I. (A) Schematic diagram of mutant plasmids containing the CARD domain (1–284 aa) or the helicase domain (218–925 aa). (B) Immunoblot analysis for detection of mutant RIG-I expressions in EBV-negative Daudi cell clones stably transfected with the deletion plasmids containing GFP-tagged CARD domain (N-RIG) or GFP-tagged helicase domain (C-RIG). Expression of N-RIG and C-RIG was detected by anti-RIG-I antibody (left panel) and also after reprobing with anti-GFP antibody (right panel). (C) Expression of type I IFN and ISGs in EBV-negative Daudi cells stably transfected with the deletion plasmids of RIG-I. The cells (5 × 106 cells each) were transfected with 30 μg of EBERs or polyI:C, and after 6 h, subjected to RT–PCR for detection of IFN-β, ISG15, and ISG56.
Figure 7
Figure 7
Binding assay for detection of association of EBERs with RIG-I. The full-length RIG-I plasmid (RIG-I/GFP) or control plasmid (containing the GFP gene only) was transfected into EBV-negative Mutu cells (Mutu(−) cells), EBER-positive EBV-infected Mutu cells ((Mutu(+) cells), and EBER-transfected Mutu cells (Mutu/EBER cells). After 48 h, cells were treated with UV irradiation, digested with RNases, and subjected to immunoprecipitation with the anti-GFP antibody. RNA was isolated from immunoprecipitants, and EBER1 and EBER2 were measured by RT–PCR.
Figure 8
Figure 8
RIG-I recognizes EBERs in the early phase of EBV infection. EBV-negative Daudi cell clones stably expressing RIG-I/GFP or GFP were infected with EBER(+) EBV or EBER(−) EBV, and expression of EBER1, EBNA2, and IFN-β was examined at the designated time of EBV infection by RT–PCR.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arrand JR, Young LS, Tugwood JD (1989) Two families of sequences in the small RNA-encoding region of Epstein–Barr virus (EBV) correlate with EBV types A and B. J Virol 63: 983–986 - PMC - PubMed
    1. Clarke PA, Schewemmle M, Schickinger J, Hilse K, Clemens MJ (1991) Binding of Epstein–Barr virus small RNA EBER-1 to the double stranded RNA-activated protein kinase DAI. Nucleic Acids Res 19: 243–248 - PMC - PubMed
    1. Foy E, Li K, Sumpter RJ, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale MJ (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 102: 2986–2991 - PMC - PubMed
    1. Glickman JN, Howe JG, Steitz JA (1988) Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein–Barr virus-infected cells. J Virol 62: 902–911 - PMC - PubMed
    1. Gregory CD, Rowe M, Rickinson AB (1990) Different Epstein–Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71: 1481–1495 - PubMed

Publication types

MeSH terms